# Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers

> **NCT03139370** · PHASE1 · TERMINATED · sponsor: **Kite, A Gilead Company** · enrollment: 16 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** KITE-718
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DEVICE:** MAGE - A3/A6 Screening Test

## Key facts

- **NCT ID:** NCT03139370
- **Lead sponsor:** Kite, A Gilead Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-12-27
- **Primary completion:** 2021-06-30
- **Final completion:** 2023-06-04
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** The study was terminated due to the sponsor's decision to discontinue the clinical trial.
- **Last updated:** 2023-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03139370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03139370, "Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03139370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*